Rick Pauls | President and Chief Executive Officer |
Kirsten Gruis | Chief Medical Officer |
Scott Kellen | Chief Financial Officer |
Thomas Flaten | Lake Street Capital Markets |
Alex Nowak | Craig-Hallum Capital Group |
Elemer Piros | ROTH Capital Partners |
Francois Brisebois | Oppenheimer |
Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Second Quarter 2022 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.
Before the company proceeds with its remarks, please note that the company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results appears in the section entitled Cautionary Statement Note regarding forward-looking statements in the company's press release issued yesterday and under the heading Risk Factors in DiaMedica's most recent annual report on Form 10-K and Form 10-Qs.